Showing results (3181-3190 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|January 25, 2015
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the EvidenceRos Wade, Ana Duarte, Mark Simmonds, et al.Pharmacoeconomics|September 7, 2012
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisalJane Burch, Susan Griffin, Claire McKenna, et al.Pharmacoeconomics|September 15, 2012
Losing sight of the wood for the trees: some issues in describing and valuing health, and another possible approachPaul Dolan, Henry Lee, Tessa PeasgoodPharmacoeconomics|July 19, 2012
Costs associated with febrile neutropenia in the USShannon L Michels, Rich L Barron, Matthew W Reynolds, et al.Pharmacoeconomics|July 14, 2012
Economic evaluations of childhood influenza vaccination: a critical reviewAnthony T Newall, Mark Jit, Philippe BeutelsPharmacoeconomics|July 14, 2012
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsVanja Sikirica, M Haim Erder, Jipan Xie, et al.Pharmacoeconomics|June 28, 2012
Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillationKate McKeagePharmacoeconomics|July 27, 2012
Counting the cost of not costing HIV health facilities accurately: pay now, or pay more laterEduard J Beck, Carlos Avila, Sofia Gerbase, et al.Pharmacoeconomics|February 10, 2015
Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary diseaseKunal Srivastava, Deepika Thakur, Sheetal Sharma, et al.Pageof 336